Safety and pharmacokinetics of oseltamivir at standard and high dosages

International Journal of Antimicrobial Agents

Volumn 35, Issue 5, 2010, Pages 461-467

  Dutkowski, R ^a   Smith, J R ^b   Davies, B E ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

High dose; Oseltamivir; Pharmacokinetics; Safety

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HEART RATE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INFLUENZA; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PR INTERVAL; PRIORITY JOURNAL; PRURITUS; QRS COMPLEX; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; T WAVE; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VITAL SIGN; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DIZZINESS; FEMALE; HEADACHE; HUMAN EXPERIMENTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NAUSEA; OSELTAMIVIR; PLACEBOS; VOMITING; YOUNG ADULT;

EID: 77949656748     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.023     Document Type: Article

References (21)

1. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005, 353:1363-1373.
2. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999, 37:471-484.
3. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. Geneva, Switzerland: WHO; 2007. [accessed 21 December 2009]. http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf.
4. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358:261-273.
5. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Geneva, Switzerland: WHO; 2009. [accessed 1 September 2009]. http://www.who.int/entity/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
6. Dutkowski R., Thakrar B., Froehlich E., Suter P., Oo C., Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003, 26:787-801.
7. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000, 355:1845-1850.
8. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000, 283:1016-1024.
9. Funck-Brentano C., Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993, 72:17B-22B.
10. Wattanagoon Y., Stepniewska K., Lindegardh N., Pukrittayakamee S., Silachamroon U., Piyaphanee W., et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009, 53:945-952.
11. Yap Y.G., Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000, 320:1158-1159.
12. Kligfield P., Gettes L.S., Bailey J.J., Childers R., Deal B.J., Hancock E.W., et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee. Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2007, 115:1306-1324.
13. Casscells S.W., Granger E., Kress A.M., Linton A., Madjid M. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular disease. Circ Cardiovasc Qual Outcomes 2009, 2:108-115.
14. Meier C.R., Jick S.S., Derby L.E., Vasilakis C., Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998, 351:1467-1471.
15. Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618.
16. Madjid M., Miller C.C., Zarubaev V.V., Marinich I.G., Kiselev O.I., Lobzin Y.V., et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007, 28:1205-1210.
17. Housworth J., Langmuir A.D. Excess mortality from epidemic influenza, 1957-1966. Am J Epidemiol 1974, 100:40-48.
18. Alling D.W., Blackwelder W.C., Stuart-Harris C.H. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am J Epidemiol 1981, 113:30-43.
19. The National Institute for Health and Clinical Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58). London, UK: NICE; 2009. [accessed 21 December 2009]. http://www.nice.org.uk/guidance/index.jsp%3Faction=byID%26o=11774.
20. Centers for Disease Control and Prevention (CDC). Neurologic complications associated with novel influenza A (H1N1) virus infection in children-Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep 2009;58:773-8.
21. Toovey S., Rayner C., Prinssen E., Chu T., Donner B., Thakrar B., et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008, 31:1097-1114.